Danziger Asaf - Jun 30, 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Executive Officer, Director
Signature
Steven Robbins, as attorney in fact for Danziger, Asaf
Stock symbol
NVCR
Transactions as of
Jun 30, 2023
Transactions value $
$12,948
Form type
4
Date filed
7/6/2023, 04:12 PM
Previous filing
Jan 9, 2023
Next filing
Aug 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $12.9K +367 +2.69% $35.28 14K Jun 30, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023.